Compare Sana Biotechnology Inc (SANA) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs State Street PDR S&P Retail ETF — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while State Street PDR S&P Retail ETF trades at $88.47. The key difference: State Street PDR S&P Retail ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | XRT | |
|---|---|---|
Market Cap | $873.84M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $5.92 | $90.88 |
52-Week Low | $2.68 | $77.28 |
Enterprise Value | $848.03M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
XRT trades at $88.94, down 0.54% today, with a bullish technical outlook from moving averages but neutral oscillators. Recent retail sales data shows five consecutive months of growth, supporting the ETF's consumer discretionary exposure. The fund offers diversified retail sector access but lacks specific valuation metrics in current data.
The ETF benefits from sustained consumer spending trends but faces headwinds from inflation and weak sentiment. Technical strength suggests near-term upside potential, though overbought RSI signals caution. Risks include macroeconomic pressures and sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
